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Abstract
Studies in human populations and mouse models of disease have linked the common leptin receptor Q223R mutation to
obesity, multiple forms of cancer, adverse drug reactions, and susceptibility to enteric and respiratory infections.
Contradictory results cast doubt on the phenotypic consequences of this variant. We set out to determine whether the
Q223R substitution affects leptin binding kinetics using surface plasmon resonance (SPR), a technique that allows sensitive
real-time monitoring of protein-protein interactions. We measured the binding and dissociation rate constants for leptin to
the extracellular domain of WT and Q223R murine leptin receptors expressed as Fc-fusion proteins and found that the
mutant receptor does not significantly differ in kinetics of leptin binding from the WT leptin receptor. (WT: ka
1.76610660.1936106 M21 s21, kd 1.21610
2460.70761024 s21, KD 6.47610
21163.30610211 M; Q223R: ka
1.75610660.02456106 M21 s21, kd 1.47610
2460.050561024 s21, KD 8.43610
21160.407610211 M). Our results support
earlier findings that differences in affinity and kinetics of leptin binding are unlikely to explain mechanistically the
phenotypes that have been linked to this common genetic variant. Future studies will seek to elucidate the mechanism by
which this mutation influences susceptibility to metabolic, infectious, and malignant pathologies.
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Introduction
Leptin is a secreted adipocytokine that regulates energy
expenditure. Centrally, leptin acts on hypothalamic circuits to
inhibit food intake. Peripherally, it stimulates immune and barrier
cells to promote activation, proliferation, resistance to cell death,
and wound repair [1]. Leptin is known to engage the cytokine
receptor homology-2 (CRH2) domain in the extracellular region of
the leptin receptor (LepR) with high affinity [2–3]. Upon leptin
binding and clustering of activated receptor complexes, Janus
Kinase 2 (JAK2) phosphorylates intracellular tyrosine residues,
which recruit transcription factors: Src Homology Phosphatase 2
(SHP2), Signal Transduscer and Activator of Transcription 5
(STAT5), and STAT3. SHP2 positively regulates the Extracellular
Signal-Regulated Kinase/c-fos (ERK/c-fos) pathway. Activated
and dimerized STAT3 translocates to the nucleus where it initiates
a transcriptional program, which includes the upregulation of
SOCS3, a feedback inhibitor of leptin signaling [4].
The Q223R encoding SNP (rs1137101) is exceedingly common
and widely distributed. According to data from the 1000 genomes
project, the overall allelic frequency is 41% A, encoding
glutamine, and 59% G, encoding arginine. Interestingly, frequen-
cies vary significantly by region and ethnicity [5]. Numerous
studies have found modest or strong association of this variant with
obesity and adiposity [6], multiple forms of cancer [7–9],
peritonitis [10], adverse drug reactions [11] and susceptibility to
enteric [12–15] and respiratory [16] infections after controlling for
ethnicity, age, sex, and environmental factors. However, studies in
separate populations have found no significant association for
several of these conditions [17–18]. In 2011, a meta-analysis of
published findings on the Q223R variant suggested that hetero-
geneity in association between this mutation and body weight in
human populations may be attributable to differences in study
design and power [19].
LepR contains two extracellular CRH domains separated by an
immunoglobulin-like domain. Two fibronectin type 3 (FN III)
domains separate the CRH2 domain from a single transmem-
brane region and a long intracellular signaling region containing a
membrane-proximal box 1 motif [2]. The LepR Q223R mutation
results from an A to G transversion encoding a glutamine to
arginine substitution in the N-terminal CRH1 domain [20]. It has
been shown that the CRH2 domain is both necessary and
sufficient for leptin binding; while CRH1 is dispensable for a high
affinity interaction [21].
To test the hypothesis that the Q223R amino acid replacement
affects ligand-binding kinetics of the leptin receptor, we measured
the leptin/LepR interaction using SPR technology on a BiaCore
T200 platform. To measure leptin association and dissociation for
both the mutant and wild type receptors, the extracellular domain
of each receptor was expressed as an Fc-fused chimera and
immobilized to a dextran matrix coated with anti-IgG antibody.
Increasing concentrations of leptin were then injected into the
system. The rates of binding and dissociation were monitored at
each leptin concentration in real-time as changes in the refractory
index of the capture surface measured in response units (RUs).
The ability to monitor these interactions in real-time allowed for
the determination of binding kinetic constants by global fitting to a
model of 1:1 ligand to receptor binding.
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Materials and Methods
Tissue Culture, Transfection, and Concentration
HEK293T/17 cells were maintained in a humidified incubator
at 37uC with 5% CO2 and cultured in HEPES buffered
Dulbecco’s Modified Eagle’s Medium-F12 (Gibco) supplemented
with 10% heat-inactivated fetal bovine serum (FBS). pMET7
constructs encoding the WT or Q223R extracellular domain of
the murine LepR, C-terminally fused to the Fc region of murine
IgG1, a FLAG-tag, and a 6x His tag were obtained from the
Cytokine Receptor Lab at Ghent University. Sequences of the WT
and Q223R constructs were confirmed by Sanger sequencing with
T7 primers provided by Genewiz, inc. When HEK293T/17 cells
were between 70 and 90% confluent, transfection using Lipofec-
tamine 2000 (Invitrogen) was performed per the product
instructions using WT, Q223R, or empty vector plasmid DNA.
12 hours after transfection, monolayers were washed and growth
medium was replaced with serum free Optimem (Gibco)
supplemented with 2 mM sodium butyrate. 48 to 72 hours later,
supernatants were harvested and cleared of cellular debris by
centrifugation.
Cleared supernatants were concentrated 20x in Amicon Ultra
15 ml centrifugal filter devices with a nominal molecular weight
limit of 100 kDa at 30006g for 15 minutes. Buffer exchange to 1x
PBS was performed following the instructions of the filtration
device manufacturers (Millipore) before BiaCore analysis.
Immunoblotting
Supernatants were heated to 95uC in 4 x SDS-PAGE sample
buffer for 5 minutes and separated by molecular weight using
SDS-PAGE in Mini-PROTEAN TGX Precast Gels (4–20%).
Replicate gels were either stained using Coomassie blue or
proteins were transferred to polyvinylidene difluoride (PVDF)
membranes by standard wet transfer methods. PVDF membranes
were blocked with 5% milk in tris-buffered saline20.05% Tween
20 (TBST) for 1 hr. Blots were either probed in two steps using
anti-murine LepR (R&D) and a horseradish peroxidase (HRP)-
conjugated secondary antibody (Sigma Aldrich) or in one step
using HRP-conjugated anti-mouse IgG1 (Sigma Aldrich). Ab
specific HRP-conjugated anti-mouse IgG1 was used as a control
for non-specific binding to residual IgG components in the
expression medium. Blots were washed 3 times for 5 minutes in
TBST between probing steps and antibody bound proteins were
visualized with ECL reagents (Pierce). Stained gels were imaged
using a typhoon fluorescent imager (GE).
Surface Plasmon Resonance
The BiaCore biosensor T200, CM5 biosensor chips, N-
hydroxysuccinimide (NHS), N-ethyl-N-(3-diethylaminopropyl)car-
bodimid (EDC), ethanolamine-HCl, and HBS-EP buffer were
obtained from BiaCore AB (GE). Rabbit polyclonal anti-mouse
IgG1 was purchased from GE Healthcare. Recombinant murine
leptin (MW 16 kDa) was obtained from R&D Systems Europe,
Ltd. Anti-mouse IgG1 was immobilized on two channels of a
carboxymethyl dextran chip (CM5) by amine coupling to the
dextran matrix, activated with NHS/EDC for 5 minutes. The
antibody was injected at 200 mg/ml in sodium acetate buffer
(10 mM, pH 4.0). Approximately 2000 resonance units (RU) of
antibody were coupled in each channel for each experiment.
Blocking of the activated surface was achieved with a 5 minute
injection of 1 M ethanolamine (pH 8.5).
A typical run at 25uC involved the injection of 100-200 ml of
Amicon-concentrated extracellular murine leptin receptor Fc
(LepRec-Fc) chimera to achieve 100–300 RU of immobilized
receptor. The surface was equilibrated for 6 minutes prior to leptin
or HBS-EP buffer injection. A range of leptin concentrations
(1.25–60 nM) was tested for each receptor chimera and their
association was monitored for 600 seconds. The dissociation phase
was monitored for 1000 seconds before regeneration of the surface
using 10 mM glycine, pH 2.0. The flow rate was set to 30 ml/min.
To monitor nonspecific binding, an antibody-coated channel
lacking bound LepRec-Fc was run with leptin and HBS-EP buffer.
Sensorgrams were generated from reference-subtracted leptin
binding data for each receptor.
Statistics and Data Analysis
Kinetic parameters were derived using BIA evaluation software
3.1 (BiaCore AB). A non-linear least squares analysis model for 1:1
binding was applied to fit data from association and dissociation
phases simultaneously and globally across all leptin concentrations
tested. Means and SEM were calculated from two separate
experiments at the indicated concentrations of leptin. A student’s
Figure 1. Expression and isolation of recombinant murine
LepRec-Fc fusion proteins. a) Expression of murine LepRec-Fc
constructs in adherent HEK293T/17 cells. Supernatants containing
LepRec-Fc chimera proteins from 24 and 48 hours post-transfection
were cleared of cellular debris, subjected to SDS PAGE and western
blotted with antibodies against domains of murine IgG1 (Fc specific for
lanes 1–5 and Ab specific for lanes 6–8). Lane 1: Mock transfected at
48 hours. Lane 2: WT transfected at 24 hours. Lane 3: WT transfected
at 48 hours. Lane 4: Q223R transfected at 24 hours. Lane 5: Q223R
transfected at 48 hours. Lane 6: Mock transfected at 48 hours. Lane 7:
WT transfected at 48 hours. Lane 8: Q223R transfected at 48 hours. b)
Concentration and buffer exchange of murine LepRec-Fc chimeras.
Supernatants were collected 48 hours after growth medium was
replaced with expression medium (serum free Optimem +2 mM sodium
butyrate). These supernatant preparations were concentrated by
Amicon ultrafiltration (NMWCO of 100 kDa). Supernatants, concen-
trates, and filtrates from each chimera were subjected to SDS-PAGE
followed by coomassie staining (top) and western blotting with a-
murine IgG1 specific to the Fc region (bottom). Lane 1: Expression
medium. Lane 2: WT supernatant. Lane 3: WT concentrate. Lane 4:
WT filtrate. Lane 5: Q223R supernatant. Lane 6: Q223R Concentrate.
Lane 7: Q223R Filtrate. c) Supernatants, concentrates, and filtrates (as
in b) from each chimera were subjected to SDS-PAGE followed by
transfer to PVDF membrane and western blotting with a-murine leptin
receptor (R&D scientific). Lane 1: Expression medium. Lane 2: WT
supernatant. Lane 3: WT concentrate. Lane 4: WT filtrate. Lane 5:
Q223R Filtrate. Lane 6: Q223R Concentrate. Lane 7: Q223R superna-
tant.
doi:10.1371/journal.pone.0094843.g001
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t-test was performed on rates of association and dissociation for
each receptor.
Results
Expression and concentration of LepRec-Fc chimeras
Q223R and WT murine LepRec-Fc chimeras were expressed in
the supernatants of adherent HEK293T/17 cells. Each prepara-
tion was concentrated by ultrafiltration with a nominal molecular
mass limit of 100 kDa. Because concentrated preparations used in
BiaCore experiments were not affinity purified, we modified the
BiaCore immobilization step to use anti-murine IgG1 as the
capture molecule instead of direct coupling. Murine leptin (the
analyte) was obtained from R&D and resuspended in phosphate
buffered saline at 1 mg/ml before dilution in BiaCore running
buffer to the appropriate concentrations. Figure 1 shows analysis
of expression (a) and concentration steps (b,c) in the preparation of
the LepRec-Fc chimeras.
Binding kinetic analysis of WT and Q223R LepRec-Fc with
recombinant leptin
Kinetic parameters were derived from global Langmuir fitting
for 1:1 binding kinetics to sensorgrams of leptin-LepR binding at
1.25, 2.5, 5, 6.25, 10, and 60 nM murine leptin. Values for the on
rate (ka), off rate (kd), and dissociation constant (KD) were derived
from global fits from two separate experiments using indepen-
dently prepared protein for the WT and Q223R chimera
receptors. Figure 2 shows representative sensorgrams depicting
leptin binding and dissociation with reference surface background
subtracted alone (Figure 2a) and overlaid with globally fitted
curves to the 1:1 model of leptin binding (Figure 2b) for WT and
Q223R. Binding and dissociation are shown in response units
(RU). Because the preparations containing the WT receptor
contained less protein than the Q223R preparations, less of the
WT chimera was immobilized before leptin binding and a lower
maximum concentration was bound during the kinetic runs.
However, sufficient receptor was immobilized to derive kinetic
constants for each run and differences of this magnitude are
unlikely to alter kinetic determinations.
Two subnanomolar affinity interactions were detected and
monitored in our system to derive kinetic constants for each
receptor. Standard errors were calculated and student’s t-tests
performed on data from two separate experiments for the three
parameters. Derived constants are summarized in Table 1. No
significant difference was measured and we concluded that the
Q223R amino acid replacement does not significantly alter 1:1
binding kinetics of murine leptin binding to the murine leptin
receptor.
Discussion
The most important finding of this work is that the common
Q223R encoding SNP in the LepR extracellular domain does not
affect the rates at which leptin binds to and dissociates from its
receptor. We investigated whether the Q223R substitution could
alter ligand binding using surface plasmon resonance (SPR).
Because it is both common and non-conservative, the Q223R
amino acid replacement has been among the most studied variants
of LepR. However, the functional consequences of this variant
remain poorly defined. This mutation occurs in the CRH1
domain, which is dispensable for high affinity leptin binding, but
may have roles in downstream signaling, receptor trafficking, or
surface expression [21–23].
Stratigopoulos et al. observed no difference in adiposity between
WT and Q223R isogenic mice fed a high fat diet [20]. A recent
study found no significant association between this LepR
polymorphism and obesity in humans. However, the homozygous
Q223R encoding genotype did correlate strongly with increased
serum cholesterol and low density lipoprotein (LDL) in both obese
and non-obese subjects [24]. In addition, our earlier work has
demonstrated a dramatic association between the human Q223R
LepR mutation and amebiasis, a common cause of diarrheal
morbidity and mortality among children globally [12]. Further-
more, patients carrying the Q223R mutation are at increased risk
of Clostridium difficile colitis [15].
SPR was used to measure, in real-time, the interaction between
murine leptin and the extracellular domain of murine LepR with
or without the Q223R mutation. Until recently, the two primary
models of leptin binding have suggested leptin:LepR stoichiom-
etries of 2:2 or 2:4 [25–26]. However, a single particle electron
microscopy study by Mancour et al. provided strong evidence for a
ligand-induced native 2:2 quaternary structure for leptin and its
receptor [2]. We sought to address our primary question in a
minimalist fashion, focusing on the interaction between one
extracellular domain of the leptin receptor and one leptin
molecule. Future studies will seek to investigate the role of the
Q223R mutation in oligomerization of the extracellular domain,
which could explain mechanistically attenuated leptin signaling
observed in cells transfected with this variant [14].
Using SPR, Mistrik et al. measured values similar, but not
identical, to our own for ka, kd, and KD with murine leptin and
murine extracellulary LepR bivalently fused to an Fc domain
Figure 2. Surface plasmon resonance kinetic analysis of leptin binding to Q223R and WT murine LepRec-Fc fusion proteins. a)
Sensorgrams from SPR experiments using Amicon-concentrated WT and Q223R murine LepRec-Fc chimeras and recombinant murine leptin at
concentrations from 1.25 to 60 nM. After receptor immobilization on a chip coated with Fc specific a-murine IgG1, each concentration of leptin was
injected for an association time of 600 seconds followed by 1000 seconds of monitoring ligand dissociation. b) Following background subtraction,
kinetic parameters were derived from global analysis of sensorgrams based on a model of Langmuir (1:1) binding kinetics using BiaCore T200
software for both WT and Q223R sensorgrams. Fitted curves (thin black lines) are overlaid on sensorgrams to demonstrate fitting to the binding
model.
doi:10.1371/journal.pone.0094843.g002
Table 1. Association and dissociation kinetics of Q223R and
WT LepRec-Fc fusions.
LepR type ka (10
6 M21 s21) kd (10
24 s21) KD (10
211 M) x2
WT 1.7660.193 1.2160.707 6.4763.30 0.13–0.151
Q223R 1.7560.0245 1.4760.0505 8.4360.407 0.26–0.35
P value 0.931 0.744 0.615 ______
Kinetic constants derived from two independent binding affinity studies for
each receptor (mean 6 standard error). Association (ka) and dissociation
constants (kd) were measured in real time using surface plasmon resonance for
the WT and Q223R extracellular murine LepR-mFc fusion chimeras. P-values
were determined using a student’s t-test and data from two kinetic runs for
each receptor. A p-value of less than 0.05 would have been considered
significant. The range of x2 values is included to assess closeness of fit to the
model of 1:1 binding used in our analyses. x2,2 is indicative of acceptable fit to
the model.
doi:10.1371/journal.pone.0094843.t001
Kinetics of Q223R LepR Ligand Binding
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e94843
(1.56106 M21s21, 76106 s21, and 0.5 nM respectively) [26].
Alternative approaches using radioligand binding have also
yielded dissociation constants in the sub-nanomolar range [27–
28]. However, Mancour et al. measured a markedly different KD
between murine leptin and the extracellular domain of murine
LepR (17 nM) using isothermal titration calorimetry [2]. Studies
specifically comparing SPR to ITC have yielded comparable
dissociation constants for multiple molecular interactions [29].
However, a systemic comparison of techniques will be required to
satisfactorily address discrepancies in parameters derived by these
two technologies for the leptin receptor.
One limitation of SPR is the challenge of modeling molecular
interactions with low dissociation rates. The difference between
the KD value that we measure and that determined using SPR by
Mistrik et al. is due largely to differences in measured dissociation
rates (kd). Even after 1000 seconds of monitoring in our system,
only a fraction of bound ligand had dissociated from both mutant
and WT receptor. This observation could in part be due to
rebinding of leptin during the dissociation phase, a common
confounding variable in SPR. It is also possible that a small
contribution of mass transport in our study complicated accurate
derivation of kinetic constants. Despite these limitations, the key
finding of our work was internally consistent and indeed supports
the conclusion that no significant difference in binding kinetics
exists between Q223R and WT LepR.
It remains possible that this mutation alters cell-signaling
networks by affecting surface expression, oligomerization kinetics,
or receptor turnover. In fact, we have shown previously using a
STAT3 driven luciferase reporter assay that cells transfected with
the Q223R receptor exhibit lower signaling via STAT3 relative to
cells expressing WT LepR [14]. Furthermore, Zabeau et al.,
showed that deletion of the entire CRH1 domain altered optimal
downstream signaling via JAK2 [23]. The current study demon-
strates clearly that these signaling phenotypes are unlikely to arise
from kinetics of receptor-ligand binding and represents a step
toward understanding how a mutation in the distal CRH1 domain
of the leptin receptor affects human health and disease.
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